Karachi: Abbott Laboratories (Pakistan) Limited has formally approved a series of resolutions during its 76th Annual General Meeting, which was conducted on April 23, 2025, both in Karachi and virtually. The company, a significant player in the pharmaceutical sector, adhered to Regulation No.5.6.9 (b) of the Pakistan Stock Exchange (PSX) Rule Book by providing a certified copy of the resolutions passed.

The meeting's agenda included ordinary business items, with primary resolutions being approved by the shareholders. Firstly, the Audited Financial Statements for the fiscal year ending December 31, 2024, alongside the Directors' Report and the Chairman's Review Report, received approval. These documents provide insights into the company's financial health and operational performance over the past year.

Another critical resolution involved the declaration of a Final Cash Dividend. Shareholders on record as of the close of business on April 15, 2025, will receive a dividend of Rs. 10.0 per share. This resolution reflects the company's commitment to delivering value to its shareholders.

Additionally, the appointment of EY Ford Rhodes, Chartered Accountants, as the auditors for the upcoming year was confirmed. This firm will hold office from the conclusion of the current Annual General Meeting until the next, providing auditing services and allowing company directors to determine their remuneration.

According to information available from the Pakistan Stock Exchange (PSX), these resolutions align with the ongoing regulatory compliance requirements, ensuring transparency and accountability in the company's financial dealings. The adherence to such standards is crucial for maintaining investor confidence and market integrity. Abbott Laboratories (Pakistan) Limited continues to position itself as a key entity within the pharmaceutical market category, focusing on strategic resolutions that support its growth and operational stability.